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Results: Using the PISA method 76 patients (34%) had severe AR. Sensi-
tivity, specificity, VPP, VPN of the recommended thresholds of the 4 semi-
quantitative methods for severe AR based on ERO are presented in the Table.
Overall, semi-quantitative methods had a good specificity but a poor sensi-
tivity except the VC which presented both a good sensitivity and specificity. 
Conclusion: For assessment of AR severity, current thresholds are specific
but poorly sensitive except the VC which provides a correct discriminative
value. Thus, semi-quantitative methods should be integrated in the comprehen-
sive evaluation of AR severity but severe AR should not be excluded only
based on semi-quantitative criteria. Our results emphasize the need for quanti-
tative assessment of AR severity in clinical practice and may explain the better
prognostic value of quantitative methods than traditional variables.
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Introduced in 1986 as a therapeutic option for degenerative aortic stenosis,
balloon aortic valvuloplasty (BAV) knows actually a new development and
has become a faster, safer and more efficient with marked technological
improvements. However, early restenosis remains the Achilles’ heel for the
long term outcome. Actually, many critically ill patients declined for surgical
aortic valve replacement could undergo a BAV followed by whether a trans-
catheter aortic valve implantation (TAVI) or a conventional aortic valve
replacement (AVR).
In this study, we aimed to analyze the long-term outcome after BAV strat-
ified by subsequent treatments.
From 2005 to 2008, 323 patients were treated by BAV with a retrograde
trans-femoral approach. Mean age was 80 ± 10 years. Mean Euroscore was
18.3±12.6%. After BAV, effective orifice area increased from 0.68±0.24 to
1.12±0.39cm2 (p<0.001) and mean gradient decreased from 44±19 to
20±11mmHg (p<0.001). Early mortality rate (<7days) was 3.4% (n=11).
Hemodynamic data controlled in 90 patients (27.9%) before any other treat-
ment and within a delay of 9±8.5 months showed a significant re-increase of
mean gradient to 35±15.1 mmHg (p<0.001). 
At long term, 210 patients received medical treatment alone, 31(9.6%)
patients underwent surgical aortic replacement, 54 (16.7%) had a trans-cath-
eter aortic valve implantation (TAVI) and 28 (8.7%) had repeat BAV at least
one time with a delay of 7.3±9.8, 5.9±6.1 and 9.8±8.5 months respectively.
With a Kaplan-Meier analysis, survival after isolated BAV was very poor
(5.1% at 5 years), whereas patients treated by BAV followed by AVR or
TAVI had a significantly better survival rate (55.7% at 5 years). 
BAV leads to short term hemodynamic improvement in patients with aortic
stenosis. This helps to bridge some critical situations allowing to further per-
form a more radical treatment in better clinical conditions. 
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Transcatheter aortic valve implantation (TAVI) induces a certain amount of
myocardial injury assessed by an increase in cardiac troponin after the proce-
dure. The goal of this study was to compare troponin levels after TAVI per-
formed using either the transfemoral (TF) or transapical (TA) route. 
Methods: We enrolled 103 consecutive pts with severe symptomatic aortic ste-
nosis and a high surgical risk who underwent TAVI using the Edwards-Sapien
valve. TF TAVI was performed in 74 pts under local anesthesia after surgical cut-
down of the femoral artery while the other 29 pts underwent a TA TAVI. For the
2 approaches, the valve was implanted during rapid pacing. Cardiac Troponin I
(lower limit of detection: 0.2 µg/l, suggested diagnostic value for myocardial inf-
arction: 1.0 µg/l) was measured before, 8 hours and 24 hours after TAVI. 
Results: Pts undergoing TA TAVI were significantly more often males (69
% vs 45 %, p<0.05), younger (79 ± 8 vs 84 ± 6 years, p<0.01) and had more
often previous bypass surgery (48% vs 23%, p<0.03) than TF pts. The propor-
tion of pts with previous myocardial infarction, previous PCI, presence of at
least one significant (>50%) coronary stenosis at the time of valve implanta-
tion, was similar between the TF and TA population. Logistic Euroscore, ejec-
tion fraction, creatinin level were similar in the 2 groups. After TAVI, the
effective orifice area increased from 0.65 ± 0.15 to 1.90 ± 0.30 cm2 (p<
0.0001) and the transvalvular mean gradient decreased from 44 ± 14 to 9 ± 4
mmHg (p<0.0001). While troponin level was similar at baseline in the TF and
TA populations (0.06 ± 0.14 µg/l TF vs 0.11 ± 0.34 µg/l TA), peak troponin
was very significantly higher after TA TAVI than after TF TAVI (65.20 ±
61.06 µg/l TA vs 5.23 ± 7.94 µg/l TF, p<0.001). 
Conclusions: Troponin elevation after TA TAVI is much higher than after
TF TAVI. Whether theses differences in the degree of myocardial injury have
prognostic value will require further studies.
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Purpose: To assess the results of first-line percutaneous aortic balloon val-
vuloplasty (PABV) in high-risk patients referred for transcatheter aortic valve
implantation (TAVI) 
Methods: Of 253 high-risk patients referred for TAVI between October 2006
and September 2009, 41 were considered transiently unsuitable for either
aortic valve replacement (AVR) or TAVI and underwent PABV as potential
bridge to intervention. In the others, primary TAVI or AVR was performed in
140 cases, and medical therapy alone in 72. 
Results: Indications for PABV were: unstable haemodynamic condition
(n=27, of whom 12 cardiogenic shocks), TAVI not immediately available for
logistic reasons (n=6), associated cancer requiring further explorations (n=4),
therapeutic test for contentious presentation (n=3), combined acute coronary
syndrome requiring urgent percutaneous revascularization (n=1). No death
occurred during PABV. Twenty-three patients actually underwent secondary
TAVI (n=19) or AVR (n=4) (bridge PABV), while 18 did not undergo further
intervention (PABV alone) because of technical (n=10) or general (n=5) con-
traindications, death before intervention (n=2) or patient's refusal (n=1). The
main baseline characteristics and clinical outcomes of the different subgroups
are presented in the Table. There was no significant difference in one-year sur-
vival between the primary TAVI / AVR and bridge PABV groups (p=0.08),
and between the medical treatment and PABV alone groups (p=0.36). 
Conclusion: In very high-risk patients with aortic stenosis and temporary
contraindications to AVR or TAVI, 1) PABV may be used as a bridge to inter-
vention with good mid-term outcomes, 2) PABV alone can be safely per-
formed but is associated with a poor mid-term outcome.
Threshold Sensitivity,
%
Specificity,
%
PPV,% NPV,% AUC
CO10l/m 38 95 81 73 0.70
VC6mm 91 77 65 95 0.90
DFR18cm/s 51 86 71 71 0.77
PHT200ms 12 100 100 60 0.81
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Severe asymptomatic aortic valve stenosis.
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Background:  Ventriculo-arterial impedance (ZVA) and Exercise echocar-
diography are new parameters proposed to best characterize patients with
aortic valve stenosis (AS).
Purpose: we sought to compare the independent value of these new indices.
Methods: we analyzed these new indices in a large prospective series of
207 consecutive patients followed for a severe asymptomatic AS.
Results: The correlations between conventional indices of aortic valve
severity, ZVA, and exercise stress echocardiography results were weak. We,
then, can  distinguish 4 distinct categories of AS patients according to ZVA
and according to the result of the exercise stress echocardiography (figure). 
Conclusion: ZVA as well as Exercise echocardiography can help but have
limitations in the decision making in regard to the management of severe
asymptomatic AS. Nevertheless, the decision to operate or not a supposed
asymptomatic patient is still multiparametric.
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Purpose: Femoral transcatheter aortic valve implantation (TAVI) is usually
done by surgical cut down under general anesthesia. Complete percutaneous
approach has become widely accepted in endovascular management of aortic
disease, and we have decided to apply this technique for TAVI. We aimed to
evaluate the impact of the sheath size on safety and efficacy of this technique.
Method:The study cohort included 64 consecutive patients who underwent
femoral approach using Prostar XL device at our institution between Mar 2008
and Feb 2010. The cohort was divided into two groups: group 1, 18 or 19 Fr
sheath (1 Prostar XL device) and group 2, 22 or 24Fr (2 Prostar XL). The iliac
and femoral angiogram was obtained before insertion and after removal of the
sheath using contralateral approach. Device success was defined as immediate
hemostasis without surgery or death related to access site during hospital stay.
Results: Clinical characteristics were similar in both groups (83.6±5.7
years, male gender 50% and logistic Euroscore 25.3±11.0%) besides higher
rate of hypertension (81.0% vs 56.1%; p=0.03) in group 1.
In group 1, Corevalve was used in 14 cases and Edwards valve in 9 cases. In
group 2, 22 Fr sheath was used in 22 cases and 24Fr in 19. 
The angiogram showed smaller femoral artery diameter in group 1 (7.7±1.2 vs
9.0±0.9mm; p=0.001 and common iliac artery 9.4±1.4 vs 11.5±1.8mm;
p=0.001), a lower calcium score (0.6±0.8 vs 1.1±0.7; p=0.034) and tortuosity
score (0.6±0.7 vs 1.2±0.7; p=0.001). Device success was achieved in 100% in
group 1 and 95.1% in group 2 (p=ns).The rate of iliac artery perforation or
rupture was lower in group 1 (0% vs 9.8%; p=0.044). Death due to access site
complication was observed only in 1 case in group 2 (p=ns).
Conclusion: Thanks to the development of lower profile devices, percuta-
neous approach for femoral arterial access is emerging as a promising method
for TAVI and will decrease the need for general anesthesia in this high risk
patients.
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The cardiac abscess formation is appraised to 20-30% during the infectious
endocarditis (IE). It is more frequent during prosthesis endocarditis and it can
reach 60%. The prognosis is generally reserved . Objective To determine
echocardiographic, bacteriological and evolutive features of prothetic IE com-
plicated of abscess.  
Retrospective study including 51 patients having certain or probable IE
according to Duke criterias between 2002 and 2005. At 9 patients (17,64%)
the endocarditis was complicated of prothetic abscess. It was about 6 men and
3 women with a middle age of 39 ±years. IE was  la ate IE in 5 cases. . Clin-
ical and biological infectious syndrome was constant. Isolated germs were sta-
phylococcus aureus in 2 cases, GRAM négatif Bacillus in 2 cases. Culture
negative endocarditis were noted in 5 cases. Brucellosis serology was positive
at one patient. Prothetic abcess was diagnosed by transthoracic echocardio-
graphy (TTE) at 2 patients and by transesophagal echocardiography (TEE) at
all patients. 
The abcess was localized on the aortic prosthesis at 5 patients, mitral pro-
thesis at 3 patients and mitroaortic prothesis at one patient. TEE identified
annular abcess at 2 patients and a myocardial abcess at 1 patient. Secondary
septic localizations were noted at 6 patients: 4 cerebral abscesses, 2 splenic
localization, a renal localization and an articular localization. High degree atri-
oventricular blocks were observed at 3 patients. The recourse to the surgery
 
Bridge 
PABV 
(n=23)
PABV alone 
(n=18)
Primary TAVI
or AVR
(n=140)
Medical 
treatment 
(n=72)
Age (years) 79±8 83±8 82±8 83±9
EuroSCORE 
(%)
35±21 39±24 25±12 31±17
Hospital 
survival (%)
100 67 88 86
One-year 
survival (%)
94±5 33±11 74±4 30±6
ZVA>5 ZVA<5
N=76 N=79
N=29 N=23
EX
 E
CH
O
+
EX
 E
CH
O
 –
Syst BP 146±21
ZVA 7.8±24
Ex ZVA 4.7±1.9
LV EF 59±10
AEA 0.9±0.2
Mean PG 42±14
Ex Mean OG 68±8
LA area 18.6±5.8
E/e´ 9.5±2.9
Ex E/e´11.3±6.2
Radial 2DS 34±17
Circum f 2DS -14.8±5.6
Long 2DS -15±3 
Syst BP 144±20
ZVA 7.0±1.6
Ex ZVA 5.1±2.3
LV EF 67±8
AEA 0.8±0.2
Mean PG 48±17
Ex Mean OG 51±19
LA area 19±5.1
E/e´11.7±5.2
Ex E/e´14±7.7
Radial 2DS 33±12
Circum f 2DS -14±4
Long 2DS -16±5
Syst BP 142±20
ZVA 4.0±0.7
Ex ZVA 4.4±1.6
LV EF 68±8
AEA 0.9±0.2
Mean PG 42±14
Ex Mean G 51±18
LA 22±5.7
E/e´11±3
Ex E/e´11±5
Radial 2DS 28±7
Circum f 2DS -13±5
Long 2DS -15±3
Syst BP 139±16
ZVA 4.2±0.6
Ex ZVA 4±1.2
LV EF 61±9
AEA 0.9±0.2
Mean PG 45±18
Ex Mean PG 62±8
LA Area 20±10
E/e´11±3
Ex E/e´11±5
Radial 2DS 28±7
Circum f 2DS -13±4.5
Long 2DS -15±3 
Characteristics of the patients
